Note de episod
In this episode, we dive into a critical regulatory update from Brazil that is sending shockwaves through the digital health community. Last week, ANVISA unexpectedly released a new instruction specifically targeting AI and Software as a Medical Device (SaMD), creating immediate hurdles for foreign manufacturers.
We break down the three core changes involving clinical data, cybersecurity, and algorithm updates. This shift presents a major challenge for companies relying on international data and standard privacy protocols for their market entry.
**Case In Point:** A German AI diagnostics…
Site: pureglobal.com

